Sunyoung Kim, DPhil

Chief Executive Officer

Sunyoung Kim, the founder and CEO of Helixmith served as Professor at Seoul National University for over 20 years after serving as Assistant Professor at Harvard Medical School. Sunyoung received his DPhil in Molecular Genetics at the University of Oxford, MS in Biochemical Engineering at MIT, MA in Microbiology and Molecular Genetics at Harvard University and held postdoctoral fellowships at Harvard Medical School and Whitehead Institute, MIT.

William Schmidt, PhD

Head of Clinical Development

Bill oversees Helixmith’s US clinical trials designed to evaluate the safety and efficacy of Engensis program. He has more than 30 years’ experience in developing pain-related medicines with special expertise in clinical studies and regulation. Bill also serves as President of North Star Consulting, Vice President of Clinical Development for EicOsis, and Chief Medical Officer for Ensysce Biosciences. Bill received his PhD in Pharmacology from University of California, San Francisco, and completed postdoctoral training at Boston University School of Medicine.

Jun Tae Park, PhD

Head of CMC

Jun supervises licensing and regulatory affairs of the company. Before joining Helixmith, Jun served over 11 years at the US FDA in charge of BLA reviews and scientific research evaluating manufacturing processes and assessing product quality for biopharmaceutical products, after working for Alpha-Beta Technology, Inc. and the US Department of Defense. Jun earned his MS in Chemical Engineering at KAIST (Korea Advanced Institute of Science and Technology) and Worcester Polytechnic Institute, and his doctorate in Biochemical Engineering at Worcester Polytechnic Institute.

Cindy Fisher, PhD, RAC

Head of Regulatory Affairs

Cindy is a regulatory affairs professional with extensive product development experience in biologics and pharmaceuticals from over 15 years of work at Vical Incorporated. Just before joining Helixmith, Cindy served as Vical’s Regulatory Lead on infectious disease vaccines and antimicrobial products. She earned her PhD in Physical Organic Chemistry from University of California, Irvine, and BS in Chemistry from University of California, Los Angeles and was a postdoctoral fellow at the Agouron Institute and the Scripps Research Institute.

Gary Neumann

Head of Quality

Gary is responsible for the global quality management of Helixmith’s investigational products, leveraging his extensive experience in the field working at companies including Vital Therapies, Shire Pharmaceuticals, Ipsen/Tercica, Novartis/Chiron Corp, and Genentech. He studied Biology at the University of California, Santa Barbara.

Seungshin Yu, PhD

Head of Bio Division and Intellectual Property

As one of the founding members of Helixmith, Seungshin served as Managing Director of Strategic Business Development until August 2018 after serving as Head of R&D of the company. She worked as Senior Scientist at the R & D Center of Takara Bio Inc. from 2005 to 2008. Seungshin received her MS and PhD in Virology at Seoul National University and did her postdoctoral fellowship at Whitehead Institute, MIT.

Haksun Moon

Head of Corporate Development & Strategy

Haksun has extensive experience in major therapeutic areas, e.g., oncology, CV, CNS and transplantation and functions such as medical, sales, marketing, and general management. Just before joining Helixmith, Haksun served as President and CPO Head of Novartis Korea after serving as President and CPO Head of Novartis Taiwan. He also worked as General Manager of the Oncology Business Unit of Novartis Korea and Global Brand Manager of CV at Novartis Pharma AG, Switzerland. Haksun earned his BS in Biology from Kyung-Hee University and MBA from Sungkunkwan University.

Michael Na

Chief Financial Officer

Before joining Helixmith, Michael served as CFO of Insstek Inc., equity analyst & strategist at Nomura Financial Investment, and co-founder of Keystone Investment Partners. He also worked as equity analyst at Macquarie Securities Korea and Daewoo Securities, senior consultant at Deloitte & Touche LLP and client associate at Merrill Lynch.

Jehee Suh, MBA

Head of Global Business Strategy and Business Development

Before joining Helixmith, Jehee worked as a Partner at McKinsey & Company, specializing in the area of Pharmaceuticals & Medical Products, and as brand manager at Novartis for the area of Cardiovascular and Metabolism. He received his MBA from the Wharton School of the University of Pennsylvania and BS in Biology from Seoul National University.